Schlafen 11 (SLFN11), a regulator of cell fate following DNA injury, sensitizes tumor cells to DNA-damaging agents. Patients with SLFN11-positive tumors may benefit from DNA-damaging chemotherapies. SLFN11 has been studied in different types of cancer including colorectal carcinomas. However, colorectal carcinomas with diffuse positivity (expression in ≥80% of tumor cells) have not been meticulously characterized. SLFN11 immunostaining of tumor microarrays (TMAs) with 3,300 primary CRCs identified 65 (~2.0%) tumors with focal staining (<10% of tumor nuclei positive), 83 (~2.5%) with patchy (≥10% and <80%) and 51 (~1.5%) with diffuse (≥80%) SLFN11 positivity. The latter was confirmed on full sections from donor blocks in 31 (~1%) cases, which were further studied including evaluation of additional immunohistochemical markers, genotyping with targeted DNA sequencing, and assessment of microsatellite instability. SLFN11-positive carcinomas were mostly (21/31, 68%) right-sided tumors with a female predominance (21/31, 68%) and median age of 67 years. Eighteen of 31 (58%) contained areas of mucinous differentiation. Deficiency of mismatch repair proteins was detected in 65% (20/31) of SLFN11-positive carcinomas. Moreover, MLH1 (n = 2), MSH2, MSH6, and PMS2 germline mutations were identified in 25% (5/20) of patients with mismatch repair deficient tumors. BRAF p.V600E mutation was found in 45% (9/20) of mismatch repair deficient, but only 1 of 11 proficient tumors. Colorectal carcinomas with diffuse SLFN11 positivity were often mismatch repair deficient tumors with their typical clinical, morphological, and molecular characteristics.

Bioptical Laboratory Ltd Plzen Czech Republic

Department of Clinical and Experimental Pathology Wrocław Medical University Wrocław Poland

Department of Molecular Diagnostics Holycross Cancer Center Kielce Poland

Laboratory of Pathology National Cancer Institute Bethesda MD USA

Sikl's Institute of Pathology Faculty of Medicine and Teaching Hospital in Plzen Charles University Plzen Czech Republic

Zobrazit více v PubMed

Murai J, Thomas A, Miettinen M, et al. Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA‐targeting anti‐cancer therapies. Pharmacol Ther 2019; 201: 94–102. PubMed PMC

Jo U, Pommier Y. Structural, molecular, and functional insights into Schlafen proteins. Exp Mol Med 2022; 54: 730–738. PubMed PMC

Murai J, Tang SW, Leo E, et al. SLFN11 blocks stressed replication forks independently of ATR. Mol Cell 2018; 69: 371–384.e6. PubMed PMC

Winkler C, Armenia J, Jones GN, et al. SLFN11 informs on standard of care and novel treatments in a wide range of cancer models. Br J Cancer 2020; 124: 951–962. PubMed PMC

Willis SE, Winkler C, Roudier MP, et al. Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response. Br J Cancer 2021; 125: 1666–1676. PubMed PMC

Lok BH, Gardner EE, Schneeberger VE, et al. PARP inhibitor activity correlates with slfn11 expression and demonstrates synergy with temozolomide in small cell lung cancer. Clin Cancer Res 2017; 23: 523–535. PubMed PMC

Taniyama D, Sakamoto N, Takashima T, et al. Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum‐based chemotherapy. Cancer Sci 2022; 113: 784–795. PubMed PMC

Hamada S, Kano S, Murai J, et al. Schlafen family member 11 indicates favorable prognosis of patients with head and neck cancer following platinum‐based chemoradiotherapy. Front Oncol 2023; 12: 978875. PubMed PMC

Tang SW, Thomas A, Murai J, et al. Overcoming resistance to DNA‐targeted agents by epigenetic activation of schlafen 11 (SLFN11) expression with class I histone deacetylase inhibitors. Clin Cancer Res 2018; 24: 1944–1953. PubMed PMC

Nogales V, Reinhold WC, Varma S, et al. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs. Oncotarget 2015; 7: 3084–3097. PubMed PMC

Jo U, Murai Y, Chakka S, et al. SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors. Proc Natl Acad Sci U S A 2021; 118: e2015654118. PubMed PMC

Murai J, Feng Y, Yu GK, et al. Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition. Oncotarget 2016; 7: 76534–76550. PubMed PMC

Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74: 229–263. PubMed

Kaczorowski M, Ylaya K, Chłopek M, et al. Immunohistochemical evaluation of Schlafen 11 (SLFN11) expression in cancer in the search of biomarker‐informed treatment targets: a study of 127 entities represented by 6658 tumors. Am J Surg Pathol 2024; 48: 1512–1521. PubMed

He T, Zhang M, Zheng R, et al. Methylation of SLFN11 is a marker of poor prognosis and cisplatin resistance in colorectal cancer. Epigenomics 2017; 9: 849–862. PubMed

Lasota J, Chłopek M, Wasąg B, et al. Colorectal adenocarcinomas harboring ALK fusion genes: a clinicopathologic and molecular genetic study of 12 cases and review of the literature. Am J Surg Pathol 2020; 44: 1224–1234. PubMed PMC

Weiser MR. AJCC 8th edition: colorectal cancer. Ann Surg Oncol 2018; 25: 1454–1455. PubMed

Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology 2020; 76: 182–188. PubMed PMC

Chan AOO, Broaddus RR, Houlihan PS, et al. CpG island methylation in aberrant crypt foci of the colorectum. Am J Pathol 2002; 160: 1823–1830. PubMed PMC

Tian L, Song S, Liu X, et al. Schlafen‐11 sensitizes colorectal carcinoma cells to irinotecan. Anticancer Drugs 2014; 25: 1175–1181. PubMed

Deng Y, Cai Y, Huang Y, et al. High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin‐based treatment. BMC Cancer 2015; 15: 1–7. PubMed PMC

Takashima T, Sakamoto N, Murai J, et al. Immunohistochemical analysis of SLFN11 expression uncovers potential non‐responders to DNA‐damaging agents overlooked by tissue RNA‐seq. Virchows Arch 2021; 478: 569–579. PubMed PMC

Ballestrero A, Bedognetti D, Ferraioli D, et al. Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer. J Transl Med 2017; 15: 199. PubMed PMC

Rajagopalan H, Bardelli A, Lengauer C, et al. Tumorigenesis: RAF/RAS oncogenes and mismatch‐repair status. Nature 2002; 418: 934. PubMed

French AJ, Sargent DJ, Burgart LJ, et al. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res 2008; 14: 3408–3415. PubMed PMC

Muzny DM, Bainbridge MN, Chang K, et al. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330–337. PubMed PMC

Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD‐1 blockade. Science 2017; 357: 409–413. PubMed PMC

Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair‐deficient or microsatellite instability‐high colorectal cancer (CheckMate 142): an open‐label, multicentre, phase 2 study. Lancet Oncol 2017; 18: 1182–1191. PubMed PMC

André T, Shiu K‐K, Kim TW, et al. Pembrolizumab in microsatellite‐instability–high advanced colorectal cancer. N Engl J Med 2020; 383: 2207–2218. PubMed

Morris VK, Kennedy EB, Baxter NN, et al. Treatment of metastatic colorectal cancer: ASCO guideline. J Clin Oncol 2023; 41: 678–700. PubMed PMC

Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil‐based adjuvant therapy in colon cancer. J Clin Oncol 2010; 28: 3219–3226. PubMed PMC

Llosa NJ, Cruise M, Tam A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter‐inhibitory checkpoints. Cancer Discov 2015; 5: 43–51. PubMed PMC

Lin A, Zhang J, Luo P. Crosstalk between the MSI status and tumor microenvironment in colorectal cancer. Front Immunol 2020; 11: 552467. PubMed PMC

Phillips SM, Banerjea A, Feakins R, et al. Tumour‐infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic. Br J Surg 2004; 91: 469–475. PubMed

Du W, Frankel TL, Green M, et al. IFNγ signaling integrity in colorectal cancer immunity and immunotherapy. Cell Mol Immunol 2021; 19: 23–32. PubMed PMC

Borrego AR, Corona‐Ayala C, Salvador JC, et al. Gene expression regulation of the type I interferon‐induced protein Schlafen 11. FASEB J 2020; 34: 1.

Mezzadra R, De Bruijn M, Jae LT, et al. SLFN11 can sensitize tumor cells towards IFN‐γ‐mediated T cell killing. PLoS One 2019; 14: e0212053. PubMed PMC

Murai Y, Jo U, Murai J, et al. Schlafen 11 expression in human acute leukemia cells with gain‐of‐function mutations in the interferon‐JAK signaling pathway. iScience 2021; 24: 103173. PubMed PMC

Yuan W, Deng D, Jiang H, et al. Hyperresponsiveness to interferon gamma exposure as a response mechanism to anti‐PD‐1 therapy in microsatellite instability colorectal cancer. Cancer Immunol Immunother 2019; 68: 257–268. PubMed PMC

Zhou C, Weng J, Liu C, et al. Disruption of SLFN11 deficiency‐induced CCL2 signaling and macrophage M2 polarization potentiates anti‐PD‐1 therapy efficacy in hepatocellular carcinoma. Gastroenterology 2023; 164: 1261–1278. PubMed